| Intralymphatic interleukin-2 in combination with zidovudine for the therapy of patients with AIDS. | |
| | |
MedLine Citation:
|
PMID: 9861562 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In a pilot study the safety and therapeutic effects of an immunostimulatory intralymphatic treatment with natural human interleukin-2 (IL-2) in combination with zidovudine were evaluated in nine patients with AIDS. Therapy with IL-2 consisted of one subcutaneous injection of 0.1 microgram/kg IL-2, followed by four intralymphatic IL-2 infusions of 0.1 microgram/kg each within a period of up to 15 days. Enlargement of lymph nodes was seen in six and a transient increase of CD4 cells in five out of nine persons in association with the IL-2 therapy. An increase of HIV p24-antigenemia was observed only in the two patients in whom zidovudine dosage had to be reduced because of side effects. Moderate clinical side effects occurred in eight of the nine patients. Four patients developed zidovudine associated anemia. Six participants showed a favourable course of disease with survival of 25 to 54 months (median 30 months) despite a previous diagnosis of manifest AIDS before IL-2 therapy. This pilot study demonstrates that a combination therapy with intralymphatic IL-2 and zidovudine can induce positive immunomodulatory effects, even in the presence of manifest AIDS. Further studies should explore the tolerability and effects of a prolonged therapy with IL-2 in combination with a more potent antiviral drug combination therapy. |
| | |
Authors:
|
T Harrer; J Schwab; W G Struff; M Schmitt; J H Ficker; W Rödl; H Parsch; J R Kalden; M Gramatzki |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Infection Volume: 26 ISSN: 0300-8126 ISO Abbreviation: Infection Publication Date: 1998 Nov-Dec |
Date Detail:
|
Created Date: 1999-03-08 Completed Date: 1999-03-08 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0365307 Medline TA: Infection Country: GERMANY |
Other Details:
|
Languages: eng Pagination: 368-74 Citation Subset: IM; X |
Affiliation:
|
Medizinische Klinik III, Universität Erlangen-Nürnberg, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acquired Immunodeficiency Syndrome
/
drug therapy* Adult Anti-HIV Agents / administration & dosage* CD4 Lymphocyte Count CD8-Positive T-Lymphocytes Disease Progression Drug Administration Schedule Drug Therapy, Combination Female Follow-Up Studies HIV Core Protein p24 / blood HIV-1* Humans Injections, Intralymphatic Injections, Subcutaneous Interleukin-2 / administration & dosage* Lymph Nodes / pathology Lymphocyte Count Male Middle Aged Pilot Projects Treatment Outcome Zidovudine / administration & dosage* |
| Chemical | |
Reg. No./Substance:
|
0/Anti-HIV Agents; 0/HIV Core Protein p24; 0/Interleukin-2; 30516-87-1/Zidovudine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A proposal for the reliable culture of Borrelia burgdorferi from patients with chronic Lyme disease,...
Next Document: Is there an effect of immunoglobulins and G-CSF on neutrophil phagocytic activity in preterm infants...